* Clofarabine ('''Clolar''') is '''a nucleoside metabolic inhibitor''' used in the therapy of [[acute lymphoblastic leukemia]] (ALL) in children.
[[File:Clofarabine.svg|thumb|right|Chemical structure of Clofarabine]]
'''Clofarabine''' is a [[purine nucleoside antimetabolite]] used in the treatment of certain types of [[cancer]], particularly [[acute lymphoblastic leukemia]] (ALL) in pediatric patients. It is a second-generation nucleoside analog designed to overcome the limitations of earlier drugs such as [[cladribine]] and [[fludarabine]].
Clofarabine works by inhibiting [[DNA synthesis]] in rapidly dividing cells. It is phosphorylated intracellularly to its active triphosphate form, which then competes with [[deoxyadenosine triphosphate]] (dATP) for incorporation into DNA. This incorporation leads to chain termination and apoptosis of the cancer cells. Additionally, clofarabine inhibits [[ribonucleotide reductase]], further depleting the pool of deoxynucleotides necessary for DNA synthesis.
== '''What are the uses of this medicine?''' ==
== Clinical Use ==
* Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with [[relapsed]] or [[refractory]] [[acute lymphoblastic leukemia]] after at least two prior regimens.
Clofarabine is primarily used in the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. It is administered intravenously and is often used in combination with other chemotherapeutic agents. The drug has shown efficacy in inducing remission in patients who have not responded to other treatments.
== Side Effects ==
== '''How does this medicine work?''' ==
Common side effects of clofarabine include myelosuppression, which can lead to [[neutropenia]], [[anemia]], and [[thrombocytopenia]]. Other side effects may include [[nausea]], [[vomiting]], [[diarrhea]], and [[hepatotoxicity]]. Due to its immunosuppressive effects, patients receiving clofarabine are at increased risk of infections.
* Clofarabine (kloe far' a been) is '''a purine analogue''' that is used in the treatment of [[acute lymphoblastic leukemia]] (ALL) in children and is used off-label in other forms of leukemia and [[myelodysplastic syndromes]]. Clofarabine is a fluorinated arabinosyladenine derivative that is '''converted intracellularly to the active triphosphate''', which is believed to '''compete with adenine triphosphate for uptake and use by DNA polymerase leading to inhibition of DNA synthesis'''.
Clofarabine is rapidly absorbed and distributed throughout the body after intravenous administration. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 5 hours, allowing for daily dosing during treatment cycles.
== Development and Approval ==
== '''Who Should Not Use this medicine ?''' ==
Clofarabine was developed to improve upon the efficacy and safety profile of earlier nucleoside analogs. It was approved by the [[Food and Drug Administration]] (FDA) in 2004 for the treatment of pediatric acute lymphoblastic leukemia. Since its approval, clofarabine has been studied in various clinical trials to explore its potential use in other hematologic malignancies and solid tumors.
* This medicine have no usage limitations.
== Related Pages ==
* [[Acute lymphoblastic leukemia]]
* [[Chemotherapy]]
* [[Nucleoside analog]]
* [[Cancer treatment]]
== '''What drug interactions can this medicine cause?''' ==
[[Category:Antineoplastic drugs]]
[[Category:Nucleoside analogs]]
* No formal drug interaction studies have been conducted with '''Clolar'''.
[[Category:Purine analogs]]
== '''Is this medicine FDA approved?''' ==
* Clofarabine was found to have activity against acute [[leukemia]] and was approved for use as an [[antineoplastic]] agent in the United States in 2004. C
* urrent indications are therapy of [[acute lymphoblastic leukemia]] in children after failure of prior therapies.
== '''How should this medicine be used?''' ==
'''Recommended dosage:'''
* Administer the recommended pediatric dose of 52 mg/m2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle.
* Repeat cycles every 2-6 weeks.
* Provide supportive care, such as intravenous infusion fluids, antihyperuricemic treatment, and [[alkalinization]] of urine throughout the 5 days of Clofarabine Injection administration to reduce the risk of tumor lysis and other adverse reactions.
* Discontinue Clofarabine Injection if hypotension develops during the 5 days of administration.
* Reduce the dose in patients with renal impairment.
* Use dose modification for toxicity.
'''Administration:'''
* Administer the recommended pediatric dose as an [[intravenous infusion]] over 2 hours daily for 5 consecutive days of a 28-day cycle.
* Repeat cycles every 2-6 weeks.
== '''What are the dosage forms and brand names of this medicine?''' ==
This medicine is available in fallowing doasage form:
* '''As Injection:''' 20 mg/20 mL (1 mg/mL) single-dose vial
This medicine is available in fallowing brand namesː
* '''Clolar'''
=='''What side effects can this medication cause?'''==
The most common side effects of this medicine include:
* vomiting
* nausea
* [[diarrhea]]
* febrile [[neutropenia]]
* [[pruritus]]
* headache
* [[Bacteremic|bacteremia]]
* [[pyrexia]]
* rash
* [[tachycardia]]
* abdominal pain
* chills
* [[fatigue]]
* [[anorexia]]
* pain in extremity
* [[hypotension]]
* [[epistaxis]]
* [[petechiae]]
==''' What special precautions should I follow?''' ==
* Clofarabine causes [[myelosuppression]] which may be severe and prolonged. May be severe and prolonged. Monitor complete blood counts and platelet counts during Clofarabine therapy.
* Serious and fatal [[hemorrhage]], including cerebral, gastrointestinal and pulmonary hemorrhage, has occurred. Monitor platelets and coagulation parameters and treat accordingly.
* Clofarabine increases the risk of infection, including severe and fatal [[sepsis]], and opportunistic infections. Monitor for signs and symptoms of infection; discontinue Clofarabine and treat promptly.
* Administration of Clofarabine may result in [[tumor lysis syndrome]] associated with the break-down metabolic products from peripheral leukemia cell death. Anticipate, monitor for signs and symptoms and treat promptly.
* Clofarabine may cause a [[cytokine release syndrome]] (e.g., [[tachypnea]], [[tachycardia]], [[hypotension]], [[pulmonary edema]]) that may progress to the [[systemic inflammatory response syndrome]] (SIRS) with [[capillary leak syndrome]] and organ impairment which may be fatal. Monitor for and discontinue Clofarabine immediately if suspected.
* Patients who have previously received a [[hematopoietic stem cell transplant]] (HSCT) are at higher risk for [[veno-occlusive disease]] (VOD) of the liver following treatment with clofarabine. Monitor for and discontinue Clofarabine if suspected.
* Severe and fatal [[hepatotoxicity]], including [[hepatitis]] and hepatic failure, has occurred with the use of Clofarabine. Severe and fatal hepatotoxicity. Monitor liver function, for signs and symptoms of hepatitis and hepatic failure. Discontinue Clofarabine immediately for Grade 3 or greater liver enzyme and/or bilirubin elevations.
* Clofarabine may cause acute renal failure. Increased creatinine and acute renal failure; monitor renal function and interrupt or discontinue Clofarabine.
* Fatal and serious cases of [[enterocolitis]], including neutropenic colitis, [[cecitis]], and [[C. difficile]] colitis, have occurred during treatment with clofarabine. Serious and fatal enterocolitis, occurring more frequently within 30 days of treatment and with combination chemotherapy. Monitor patients for signs and symptoms of enterocolitis and treat promptly.
* Serious and fatal cases of [[Stevens-Johnson syndrome/toxic epidermal necrolysis|Stevens-Johnson syndrome]] (SJS) and toxic epidermal necrolysis (TEN) have been reported. Discontinue for exfoliative or bullous rash, or if SJS or TEN is suspected.
* Based on findings from animal reproductive studies and the drug's mechanism of action, Clofarabine can cause fetal harm when administered to a pregnant woman. Advise males with female partners of reproductive potential to use effective [[contraception]] during treatment with Clofarabine and for at least 3 months after the last dose.
== '''What to do in case of emergency/overdose?''' ==
Symptoms of overdosage may include:
* [[hyperbilirubinemia]]
* vomiting
* [[maculopapular rash]]
* [[hematologic]] malignancies
'''Management of overdosage:'''
* In the event of an overdose, appropriate supportive treatment should be initiated.
== '''Can this medicine be used in pregnancy?''' ==
* There are no available data on Clofarabine use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
* Clofarabine should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus.
=='''Can this medicine be used in children?'''==
* Safety and effectiveness have been established in pediatric patients 1 to 21 years old with [[relapsed]] or [[refractory]] [[acute lymphoblastic leukemia]].
== '''What are the active and inactive ingredients in this medicine?''' ==
'''Active ingredient:'''
* CLOFARABINE
'''Inactive ingredients:'''
* SODIUM CHLORIDE
* WATER
== '''Who manufactures and distributes this medicine?''' ==
'''Manufactured for:'''
* [[Fresenius (company)|Fresenius]]
* Lake Zurich, IL
* www.fresenius-kabi.com/us
* Made in India
== '''What should I know about storage and disposal of this medication?''' ==
* Vials containing undiluted Clofarabine Injection should be stored at 25°C (77°F); [[excursions]] permitted to 15°C to 30°C (59°F to 86°F).
* Do not freeze.
* Retain in carton until contents are used.
* Clofarabine is a [[cytotoxic]] drug.
* Follow applicable special handling and disposal procedures.
Clofarabine works by inhibiting DNA synthesis in rapidly dividing cells. It is phosphorylated intracellularly to its active triphosphate form, which then competes with deoxyadenosine triphosphate (dATP) for incorporation into DNA. This incorporation leads to chain termination and apoptosis of the cancer cells. Additionally, clofarabine inhibits ribonucleotide reductase, further depleting the pool of deoxynucleotides necessary for DNA synthesis.
Clofarabine is primarily used in the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. It is administered intravenously and is often used in combination with other chemotherapeutic agents. The drug has shown efficacy in inducing remission in patients who have not responded to other treatments.
Common side effects of clofarabine include myelosuppression, which can lead to neutropenia, anemia, and thrombocytopenia. Other side effects may include nausea, vomiting, diarrhea, and hepatotoxicity. Due to its immunosuppressive effects, patients receiving clofarabine are at increased risk of infections.
Clofarabine is rapidly absorbed and distributed throughout the body after intravenous administration. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 5 hours, allowing for daily dosing during treatment cycles.
Clofarabine was developed to improve upon the efficacy and safety profile of earlier nucleoside analogs. It was approved by the Food and Drug Administration (FDA) in 2004 for the treatment of pediatric acute lymphoblastic leukemia. Since its approval, clofarabine has been studied in various clinical trials to explore its potential use in other hematologic malignancies and solid tumors.
